Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B072: Resistance to the RAS inhibitor daraxonrasib due to the LZTR1 mutation in a KRAS G12D mutated pancreatic ductal adenocarcinoma patient-derived organoid model

Targeted therapy with RAS (Rat sarcoma) inhibitors are increasingly used in the treatment of pancreatic ductal adenocarcinoma (PDAC) given the prevalence of KRAS (Kirsten rat sarcoma virus) mutations in over 90% and poor prognosis with 13.7% five-year survival in this population despite standard treatment.1,2 Leu...

Alexa F. Viniotis, Jaeger Moore, R. Soldi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.